Acute kidney injury induced by anti-novel coronavirus drug simnotrelvir/ritonavir
10.3760/cma.j.cn114015-20240724-00624
- VernacularTitle:抗新型冠状病毒药物先诺特韦/利托那韦致急性肾损伤
- Author:
Fuwen YU
1
;
Yubo LIU
1
;
Shuxia TIAN
1
Author Information
1. 天津市中西医结合医院（南开医院）临床药学科，天津 300100
- Publication Type:Journal Article
- Keywords:
Acute kidney injury;
Ritonavir;
Mezlocillin;
Simnotrelvir
- From:
Adverse Drug Reactions Journal
2025;27(4):251-253
- CountryChina
- Language:Chinese
-
Abstract:
A 71-year-old female patient underwent laparoscopic right hemicolectomy due to intestinal obstruction caused by malignant colon tumor. The patient had a fever 7 hours after surgery. Because of suspected abdominal infection, intravenous infusion of 2 g mezlocillin was given once every 8 hours on the day of operation. Three days later, the patient was given simnotrelvir (0.75 g)/ritonavir (0.1 g) once every 12 hours because of the positive nucleic acid test of novel coronavirus. Two days later after medication, the patient′s serum creatinine (Scr) increased from 40.2 μmol/L before treatment to 165.1 μmol/L, and the estimated glomerular filtration rate (eGFR) decreased from 100.6 ml/(min·1.73 m 2) before treatment to 26.7 ml/(min·1.73 m 2), without significant oliguria. Drug-induced acute kidney failure (AKI) was suspected, and mezlocillin and simnotrelvir/ritonavir were discontinued. After 3 days of drug withdrawal, the patient′s renal function was improved, with Scr 78.1 μmo1/L; after 15 days, the Scr was 49.7 μmo1/L and eGFR was 93.8 ml/(min·1.73 m 2). It was considered that the patient′s AKI was likely to be related to simnotrelvir/ritonavir. However, the possibility of nephrotoxicity enhancement due to the combination of simnotrelvir/ritonavir and mezlocillin could not be excluded.
